Herein, we report that breast cancer (BC) patients can be distinguished from cancer-free (NC) controls by serum immunoglobulin G (IgG) crystallizable fragment (Fc) region N-glycosylation profiling using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). Recently, there has been much progress in the field of tumor immunology. However, to date, the role and biomarker potential of IgG Fc region N-glycosylation, which affects the function of antibodies, have not been examined in BC.
Introduction
Recent progress in tumor immunology has shown its importance in tumor biology. One of the key factors in humoral immunity is immunoglobulin G (IgG). IgG is involved in antibody-dependent cell-mediated cytotoxicity (ADCC), opsonization, and complement-dependent cytotoxicity (CDC). IgG is composed of an antigen-binding fragment (Fab) and a crystallizable fragment (Fc) region [1, 2] . The IgG Fc region contains an N-glycosylation site at asparagine 297 (Asn297) [1] ; the function of IgG is reportedly altered by N-glycosylation, which is an important post-translational modification of the protein [1, 3] . N-glycosylation is characterized by the presence or absence of the sugars galactose, sialic acid, bisecting GlcNAc, and core fucose [2] .
Although little is known about the underlying mechanisms, IgG Fc region N-glycosylation is reported to be affected by sex, age, pregnancy, autoimmune disease, and some cancers [4] [5] [6] . Reduced IgG Fc region galactose has been reported in gastric cancer, prostate cancer, and non-small cell lung cancer [4, [7] [8] [9] . However, these studies were limited in that individual analyses were performed for different sugars, and so the greater picture of IgG Fc region N-glycosylation was not captured.
To date, a detailed profile of IgG N-glycans in breast cancer (BC) patients has not been 6 produced. Here, we profiled the serum IgG Fc region N-glycans of BC patients (N = 90) and cancer-free (NC) controls (N = 54) using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). We demonstrate that BC patients exhibit a characteristic pattern of IgG Fc region N-glycosylation which can be used to distinguish BC patients from NC control using a multiple logistic regression (MLR) model. As such, IgG Fc region N-glycosylation has the potential to be used as a biomarker in breast cancer.
Materials and Methods

Serum sample collection from BC patients and NC controls
Blood was obtained from 54 healthy female volunteers and 90 female BC patients. After clot formation, serum was obtained by centrifugation (1600  g, 10 minutes at room temperature) and was stored at −80 C until required. All study protocols were approved by the Ethics Committee for Clinical Research, Kyoto University Hospital (G350 and G424).
IgG isolation from serum samples 7
IgGs were isolated from 5 l of serum using nProtein G Sepharose 4 Fast Flow (GE Healthcare, Uppsala, Sweden). Briefly, 5 l serum was diluted 100 fold in phosphate buffered saline (PBS; Takara Bio, Shiga, Japan), and incubated with Protein G at 4 C for 30 minutes. After centrifugation, the sepharose was washed 4 times in PBS and resuspended in NuPAGE LDS Sample Buffer (Invitrogen, Carlsbad, Canada) diluted with 50 mM DTT (DL-Dithiothreitol; Sigma-Aldrich Japan K.K., Tokyo, Japan). IgGs were collected in the supernatant by heating for 2 minutes at 95 C and centrifuging the sample.
SDS-PAGE and extraction of N-glycans from IgGs
To obtain the heavy chain fraction from the isolated IgGs, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed (200 V, 50 minutes) and gels were stained with Coomassie brilliant blue (Nacalai Tesque, Kyoto, Japan). The IgG heavy chain band was excised from the gel and destaining by adding 200 mM NH4HCO3, 40% acetonitrile (ACN) aq, PNGase F (Sigma-Aldrich Japan K.K.) and incubating the sample at 37 C overnight. Samples were subsequently sonicated and 8 N-glycans were extracted and purified using NuTip 10 (Carbon; Glygen, Columbia, MD, USA).
Methylamidation of N-glycan sialic acid
Dried N-glycans were treated with 500 mM methylamine hydrochloride (Sigma-Aldrich Japan K.K.), 50 mM PyAOP (7-Azabenzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluoro-phosphate (Sigma-Aldrich Japan K.K.), and 250 mM methylmorpholine in DMSO at room temperature for 1 hour. N-glycans were then purified with a free sample of Inertsil Amide 3 μm (GLscience, Tokyo, Japan) and NuTip 10 (Carbon; Glygen).
AQ-labeling with 3AQ/CA and MALDI-MS analysis
Purified N-glycans were labeled with 3AQ/CA reagent in accordance with our previous report [10] . Briefly, 3-Aminoquinoline (3-AQ) matrix substance for MALDI-MS (Sigma-Aldrich Japan K.K.) was diluted to 900 mM with 100 mM p-coumaric acid (CA) (Sigma-Aldrich Japan K.K.) in 10 mM (NH4)2SO4 (Sigma-Aldrich) and 50% ACN aq.
Dried N-glycans were resuspended in 10 l of distilled water and 0.5 l was mixed 0.5 l Shimadzu/Kratos, Manchester, UK) in the negative-ion reflectron mode. Data acquisition and processing was controlled using Shimadzu Biotech Launchpad 2.9.1 (Shimadzu/Kratos).
The intensity of the peak for each of the 32 types of N-glycans detected and the dehydrated N-glycans was estimated by normalizing the intensity of each well using the sum intensity of all of the peaks. The average value from the 9 wells for each N-glycan was used for the analysis.
MLR model development and validation
MLR was used because it is a well-established method to manage multiple variables and create a predictive model. To develop the MLR model, the relative intensity and status in BC/NC were used as independent and dependent variables, respectively.
Support vector machine-feature selection (SVM-FS) was used to rank the N-glycans based on their individual discriminative ability and the top 10 were used for stepwise feature selection. Feedback selection, with a threshold of P = 0.05, was used to eliminate redundant variables, which yielded a set of 7 minimum feature, independent N-glycans.
The receiver operative characteristic (ROC) curve and area under the ROC curve (AUC) were calculated to determine the sensitivity and specificity of the model.
To eliminate optimistic prediction, we performed rigorous validation of the model. We conducted 10-fold cross-validation (CV) that: (1) randomly split the whole dataset into training data (90%) and validation data (10%); (2) built models based on the training data and predicted the validation data; and (3) conducted (1) and (2) To estimate the versatility of the developed model, pruning tests were also performed: the feature showing the largest P-value in the MLR model was eliminated recursively, and the discriminative ability was calculated.
Analyses were conducted using WEKA (ver. 
Characteristics of BC patients and NC controls
Construction of the MLR model
To appreciate the pattern of the IgG N-glycosylation, an MLR model was developed following the scheme in Fig. 2A . To construct the model, individuals with a medical history of disease which might affect IgG glycosylation were excluded. Stage 0 BC patients were also excluded because stage 0 BC is non-invasive, and so the likelihood of immune cell contact is much reduced. BC patients who had undergone recurrence and those who were currently receiving systemic chemotherapy were also excluded to reduce the influence of past therapies ( Fig. 2A) . The clinical characteristics of the BC patients used for the model are shown in Table 1B .
The predictive ability of the model was rigorously validated and 7 N-glycans were selected using SVM-FS and stepwise feature selection. Pruning analyses was performed to appreciate the relationship between the number of variables and the accuracy of the model (Fig. 2B ). Using 7 variables (G28, G23, G13, G12, G29, G24, and G19), the model AUC was 0.874 (P < 0.0001); fewer variables reduced the accuracy of the model (Supplementary Tables S1 and S2 ). Both tests showed a relatively small difference between the upper and lower 95% CIs, indicating that the developed model was highly robust.
The probability of BC predicted by the model is depicted in Fig. 2D . There is a clear 13 distinction between the predicted probability for BC patients and NC controls; no significant difference was observed for BC patients of different stages.
Finally, the individuals which were excluded during model construction were added to the MLR 7-variable model analysis. Although the AUC was decreased to 0.834 with these patients, the model was still tolerable.
Association of clinical characteristics with the BC IgG N-glycans
We proceeded to investigate the association between the MLR model probability score and clinical factors. Surprisingly, even though ductal carcinoma in situ (DCIS) is thought to have a low probability of directly encountering immune cells, stage 0 (DCIS) BC patients showed the same pattern of IgG N-glycosylation as stage I−IV patients (Fig. 3A) .
Since it has been reported that IgG Fc region N-glycosylation changes with age, we investigated the age-dependency of our model (Figs. 3B and C) [5] . No significant relationship between the probability score and age was detected in BC patients or NC controls. The ROC curve and AUC were similar in both the age < 50 and age ≥ 50 groups (AUC = 0.881 and 0.877, respectively; Supplementary Fig. S2 ). 14 The MLR model probability score of individuals with a medical history which could affect N-glycosylation tended to be higher in both BC patients and NC controls (Fig.   3D ).
The relationship between the probability score and clinical-pathological features was also analyzed, but no significant relationships were observed (Supplementary Table S3 ).
In Supplementary Figs. S2B and S2C, the findings of the analysis for stage IV patients, those with recurrence (not receiving therapy), those receiving chemotherapy, and patients from whom repeat samples collected 1 year after curable resection were available are shown. And is IgG Fc region N-glycosylation a potential biomarker? We shall try to address these questions based on our own observations and data from other published studies.
Firstly, the mechanisms which regulate IgG Fc region N-glycosylation have not been elucidated. However, it is possible that the serum IgG N-glycan profile could be altered in the course of either IgG production, circulation in the body, or absorption. Previous reports have suggested that some stimuli, for example inflammatory cytokines, could affect IgG Fc region N-glycosylation during production [1, 11, 12] , and BC cells, including DCIS, are reported to secrete inflammatory cytokines [13] . These observations support our finding that stage 0 BC patients exhibit the same characteristic pattern of IgG N-glycosylation as later stage BC patients, even though these cells are thought to rarely encounter immune cells, and suggest that humoral factors or soluble mediators could be important in the regulation of IgG N-glycans.
Although to date there is no evidence of circulating IgG N-glycan alteration during carcinogenesis, it has been reported that reactive oxygen species can modify oligosaccharides after production [14, 15] . With regard to possible alteration of the serum IgG N-glycan profile through absorption, cytokines or other factors could affect the profile by regulating absorption; it has previously been reported that the clearance of IgGs from serum is affected by the difference in N-glycans of IgGs [16] . It has also been reported that cytokines can regulate absorption of agalactosylated IgG in macrophages [17, 18] . Although further investigation is necessary, these observations might account for the characteristic pattern of IgG Fc region N-glycosylation observed in BC patients.
Our analysis was also performed by comparing the ratio of N-glycans based on each sugar in BC patients with that in NC controls (Supplementary Table S4 ). It has previously been reported that IgG Fc region N-glycosylation can affect IgG function, and so the pattern observed in BC patients is likely to be of functional significance [1] [2] [3] [19] [20] [21] . Increased galactose is reported to increases CDC activity through C1q binding, but is not thought to affect ADCC [2] . Conversely, increase of sialic acid is reported to decrease ADCC activity through a loss of FcγRIIIa binding, and the absence of core fucose and the presence of bisecting GlucNAc is reported to increase ADCC through FcγRIIIa binding [3] . In the present study, the agalactosylation observed in BC patients is consistent with previous studies in different types of cancer [7] [8] [9] . Agalastosylation of the IgG Fc region leads to less CDC activity, which is compatible with cancer cells escaping from the immune system [22] . In rheumatoid arthritis, agalactosylation of IgG Fc regions correlates with disease activity and contributes to the disease pathogenesis [1, 23] . Although the mechanisms underlying these diseases are different, further investigation of IgG Fc region agalactosylation in cancer may be warranted. In total, bi(+)/bi(−), F(+)/F(−), Na1/Na0, and Na2/Na0 sugars were investigated, but differences between BC patients and NC controls were only observed for some pairs of fucose and bisecting GlucNAc. This suggests that immune system tolerance in BC patients might not be caused by IgG sialylation, but could be related to reduced CDC activity resulting from agalactosylation. Further studies will be required to elucidate the significance of each N-glycan pair.
The MLR model developed in the present study using IgG Fc region N-glycans had an acceptable AUC of 0.874. The advantages of the model developed were its applicability to stage 0 BC cases as well as to different kinds of breast cancer since there were no specific clinicopathological features which were associated with a reduced sensitivity, and it could be used for patients of all ages. Moreover, the analysis only requires 5 l of serum. However, since the alteration of IgG Fc region N-glycosylation was reported in other cancers [7] [8] [9] , there is a concern about the specificity for just BC, so further investigation is necessary to assess other cancers. The potential of the model for BC patient monitoring may be limited given that patient scores were not significantly different 1 year after curative resection compared with those at the time of diagnosis (Supplementary Fig. S2C ). Longer follow-up periods may be required to observe a change in IgG Fc region N-glycosylation after curative resection.
Although the sample size in the present study was small, we believe the IgG Fc region N-glycan MLR model developed has the potential to be used as a diagnostic biomarker.
In the present study, internal statistical validations (CV and bootstrap tests) were conducted to evaluate the model's generalizability (Fig. 2C) ; we concluded that the model was generalizable because of the small variation in AUC values observed in the CV tests. However, the bootstrap tests showed larger variations in AUC values (Fig. 2C ).
As such, more rigorous validation using an independent cohort is necessary to confirm the model's versatility. The pruning tests conducted in the present study indicated that at least 2 variables were necessary to yield an AUC > 0.7 (Fig. 2C) ; however, the number of variables and the specific variables required can be optimized following further investigation. Tables   Supplementary Table S1 The 7 variables included in the model 
